Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immunocore Holdings (IMCR – Research Report), Warby Parker (WRBY – Research Report) and Ocular Therapeutix (OCUL – Research Report).
Immunocore Holdings (IMCR)
Robert W. Baird analyst Jack Allen maintained a Buy rating on Immunocore Holdings on May 8 and set a price target of $84.00. The company’s shares closed last Thursday at $59.85.
According to TipRanks.com, Allen has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunocore Holdings with a $84.58 average price target, a 39.0% upside from current levels. In a report issued on April 29, Leerink Partners also initiated coverage with a Buy rating on the stock with a $74.00 price target.
See the top stocks recommended by analysts >>
Warby Parker (WRBY)
JMP Securities analyst Nicholas Jones CFA maintained a Hold rating on Warby Parker yesterday. The company’s shares closed last Thursday at $14.68.
According to TipRanks.com, CFA is a 5-star analyst with an average return of
Warby Parker has an analyst consensus of Strong Buy, with a price target consensus of $17.71.
Ocular Therapeutix (OCUL)
In a report issued on May 8, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Ocular Therapeutix, with a price target of $18.00. The company’s shares closed last Thursday at $5.84.
According to TipRanks.com, Kusy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $15.17, implying a 165.7% upside from current levels. In a report issued on May 8, JMP Securities also reiterated a Buy rating on the stock with a $22.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IMCR:
- Immunocore reports Q1 EPS (49c), consensus (37c)
- Immunocore reports first quarter financial results and provides a business update
- Immunocore initiated with an Outperform at Leerink
- Immunocore announces upcoming presentation and posters at ASCO 2024
- Immunocore to present at upcoming investor conferences
